rewrite this title and make it good for SEORevolution Medicines reports phase 1 data for lung cancer drug By Investing.com

REDWOOD CITY, Calif. – Revolution Medicines Inc. (NASDAQ:RVMD) presented updated Phase 1 clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer at the American Association for Cancer Research Annual Meeting on Sunday. The stock surged 54% over the past week and is trading near its 52-week high of $155.70.

The RMC-9805-001 trial evaluated 40 patients with KRAS G12D NSCLC treated with zoldonrasib 1200 mg once daily, the recommended Phase 2 dose, according to a press release statement. Data were as of December 1, 2025.

Among 27 patients previously treated with immune checkpoint inhibitor and platinum chemotherapy who had not received prior docetaxel treatment, the confirmed objective response rate was 52% and the disease control rate was 93%. Median progression-free survival was 11.1 months, with an estimated 12-month PFS rate of 48%.The positive trial results have pushed Revolution Medicines’ market capitalization to $31.26 billion. According to InvestingPro analysis, the stock appears overvalued at current levels. For deeper insights into RVMD’s valuation and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro.

Treatment-related adverse events of any grade occurring in at least 15% of patients included nausea (43%), vomiting (33%), diarrhea (30%), and rash (18%). The majority of treatment-related adverse events were Grade 1 in severity. Grade 3 treatment-related adverse events occurred in 13% of patients and resolved following dose interruption. Treatment-related adverse events led to treatment discontinuation in 5% of patients. No Grade 4 or Grade 5 treatment-related adverse events were observed.

Median time to response was 1.4 months. Overall survival data were immature at the time of analysis, with median overall survival not yet reached. The estimated survival rate at 12 months was 73%.

KRAS G12D represents 4% of NSCLC cases and currently lacks an approved targeted therapy. Zoldonrasib is being evaluated as a monotherapy and in combination with other therapies in lung and gastrointestinal cancers.

In other recent news, Revolution Medicines Inc. has successfully raised approximately $2.1 billion through concurrent public offerings of common stock and convertible senior notes. The company sold over 12 million shares at $142.00 each, generating around $1.7 billion in gross proceeds. Additionally, Revolution Medicines issued $500 million in convertible senior notes due in 2033 with a 0.50% annual interest rate. This financial development follows the positive outcomes of the company’s Phase III RASolute 302 trial for its cancer drug, daraxonrasib, which met key survival endpoints. The trial’s success has led to several analyst actions. Mizuho reiterated an Outperform rating with a $140 price target, while H.C. Wainwright significantly raised its price target to $169, maintaining a Buy rating. RBC Capital also increased its price target to $162, citing the company’s strong position in the RAS inhibitor market. These updates reflect growing confidence among analysts in Revolution Medicines’ future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.